VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
VaxCT
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Four-Component MUC1-diTn Conjugate Vaccine with Three T-Helper Epitopes
Vaccine Information
  • Vaccine Name: Four-Component MUC1-diTn Conjugate Vaccine with Three T-Helper Epitopes
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Type: Conjugate vaccine
  • Status: Research
  • Host Species for Licensed Use: Mouse
  • Antigen: MUC1 (Palitzsch et al., 2014)
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Description: A fully synthetic four-component antitumor vaccine consisting of a tumor-associated MUC1 glycopeptide (22-mer) bearing two TN antigens (GalNAc-?-O) at threonine-11 and serine-17, covalently conjugated to three different bacterial T-helper cell epitopes via squaric acid linkage, with potential antineoplastic activity. The vaccine includes a 14-mer from Yersinia pestis, a 15-mer from Yersinia pestis, and a 20-mer from Mycobacterium tuberculosis as T-helper epitopes, separated by flexible triethylene glycol spacers. Vaccination elicits adaptive T-cell-mediated immune responses with predominantly IgG1 antibodies that recognize tumor-associated MUC1 on human breast cancer cells. In preclinical studies, the four-component vaccine induced antibody titers approximately 8-fold higher than vaccines containing a single T-helper epitope (~30,000 vs ~4,000 endpoint titers), with 71% binding to MUC1-expressing T47D breast cancer cells and formation of immunological memory. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in an aberrant or deglycosylated form in various cancers such as those of the breast, prostate, pancreas, and ovary (Palitzsch et al., 2014).
Host Response
References
Palitzsch et al., 2014: Palitzsch B, Hartmann S, Stergiou N, Glaffig M, Schmitt E, Kunz H. A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes. Angewandte Chemie (International ed. in English). 2014; 53(51); 14245-14249. [PubMed: 25318465].